Late Effects Following Treatment of Hodgkin Lymphoma During Childhood and Adolescence. Results of the Hodgkin Lymphoma Late Effects Research Project

Abstract Survival rates have been excellent in patients treated for Hodgkin lymphoma (HL) during childhood and adolescence. Unfortunately, severe treatment related late effects have been observed. It was therefore an important aim of the cooperative pediatric HL therapy studies in Germany to reduce the number of late effects without jeopardizing the excellent treatment results. Progress and relapses of HL were analyzed to obtain important information for the future salvage therapy. All late effects were documented and their etiologies analyzed. Information obtained from bacterial infections and late deaths following splenectomy were used to inform patients at risk and their local physicians about necessary preventive measurements. Procarbazine was recognized as major gonadotoxic agent in boys and eliminated successively from the treatment regimens. Parenthood was normal in female patients when compared to the German female population documenting normal ovarian function except in patients with pelvic radiation. Radiation was the most important risk factor for thyroid diseases, cardiac late effects and subsequent malignant neoplasms, especially thyroid and breast cancer. A special screening program was initiated for women with chest radiotherapy, since they had a high risk of breast cancer already at a young age. The results of the HL Late Effects Research Project are important for the aftercare of patients and for the design of future HL treatment regimens.

[1]  J. Brämswig,et al.  Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study. , 2015, The Lancet. Oncology.

[2]  J. Brämswig,et al.  Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence. , 2015, Deutsches Arzteblatt international.

[3]  A. Hinz,et al.  Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002 , 2014, Supportive Care in Cancer.

[4]  R. Pötter,et al.  Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Begg,et al.  New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Pötter,et al.  Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow‐up project of the German–Austrian DAL‐HD studies , 2010, Pediatric blood & cancer.

[7]  A. Sigurdson,et al.  Risk of Second Primary Thyroid Cancer after Radiotherapy for a Childhood Cancer in a Large Cohort Study: An Update from the Childhood Cancer Survivor Study , 2010, Radiation research.

[8]  W. Klapper,et al.  Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Wendy Leisenring,et al.  Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. , 2010, Journal of the National Cancer Institute.

[10]  A. Whittemore,et al.  Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Ng,et al.  Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. , 2008, International journal of radiation oncology, biology, physics.

[12]  Silke Coburger,et al.  Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer , 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[13]  R. Pötter,et al.  Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yan Liu,et al.  Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study , 2005, The Lancet.

[15]  L. Robison,et al.  High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Gerald,et al.  Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence , 2003, Cancer.

[17]  R. Pötter,et al.  Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. , 2003, Klinische Padiatrie.

[18]  R. Pötter,et al.  Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  P. Inskip Thyroid cancer after radiotherapy for childhood cancer. , 2001, Medical and pediatric oncology.

[20]  D. Green,et al.  Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  H. Storm,et al.  Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Green,et al.  Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Pötter,et al.  High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Jürgens,et al.  The effects of etoposide on testicular function in boys treated for Hodgkin's disease , 1998, Cancer.

[25]  M. Hudson,et al.  Increased mortality after successful treatment for Hodgkin's disease. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Lamborn,et al.  Second cancers following pediatric Hodgkin's disease. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Parikh,et al.  Gonadal function following ABVD therapy for Hodgkin's disease. , 1997, American journal of clinical oncology.

[28]  Denis R. Miller,et al.  Literature Review: Hematology/Oncology: Risk of Subsequent Malignant Neoplasms among 1,641 Hodgkin's Disease Patients Diagnosed in Childhood and Adolescence: A Population-Based Cohort Study in the Five Nordic Countries , 1997 .

[29]  S. Hancock,et al.  Cardiac disease following treatment of Hodgkin's disease in children and adolescents. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[31]  J. Ritter,et al.  Abgestufte Chemotherapie und reduzierte Strahlendosis beim Morbus Hodgkin im Kindesalter - Ein Bericht über 170 Patienten der kooperativen Therapiestudie HD 78 , 1982 .

[32]  S. Donaldson,et al.  Complications of treatment of Hodgkin's disease in children. , 1982, Cancer treatment reports.

[33]  A. Santoro,et al.  ABVD chemotherapy in the treatment of Hodgkin's disease. , 1982, Cancer treatment reviews.

[34]  F. Wilner,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1975, Michigan medicine.

[35]  H. Kaplan Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. , 1966, Cancer research.

[36]  J. Haerting,et al.  The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma. , 2014, European journal of cancer.